Bifogade filer
Kurs & Likviditet
Kalender
2024-11-06 | Kvartalsrapport 2024-Q3 |
2024-08-15 | X-dag halvårsutdelning NOVO B 3.5 |
2024-08-07 | Kvartalsrapport 2024-Q2 |
2024-05-02 | Kvartalsrapport 2024-Q1 |
2024-03-22 | X-dag halvårsutdelning NOVO B 6.4 |
2024-03-21 | Årsstämma |
2024-01-31 | Bokslutskommuniké 2023 |
2023-11-02 | Kvartalsrapport 2023-Q3 |
2023-09-13 | Split NOVO B 1:2 |
2023-08-18 | X-dag halvårsutdelning NOVO B 6 |
2023-08-10 | Kvartalsrapport 2023-Q2 |
2023-05-04 | Kvartalsrapport 2023-Q1 |
2023-03-24 | X-dag halvårsutdelning NOVO B 8.15 |
2023-03-23 | Årsstämma |
2023-02-01 | Bokslutskommuniké 2022 |
2022-11-02 | Kvartalsrapport 2022-Q3 |
2022-08-12 | X-dag halvårsutdelning NOVO B 4.25 |
2022-08-04 | Kvartalsrapport 2022-Q2 |
2022-05-04 | Kvartalsrapport 2022-Q1 |
2022-03-25 | X-dag halvårsutdelning NOVO B 6.9 |
2022-03-24 | Årsstämma |
2022-02-02 | Bokslutskommuniké 2021 |
2021-11-03 | Kvartalsrapport 2021-Q3 |
2021-08-16 | X-dag halvårsutdelning NOVO B 3.5 |
2021-08-05 | Kvartalsrapport 2021-Q2 |
2021-05-05 | Kvartalsrapport 2021-Q1 |
2021-03-26 | X-dag halvårsutdelning NOVO B 5.85 |
2021-03-25 | Årsstämma |
2021-02-03 | Bokslutskommuniké 2020 |
2020-10-30 | Kvartalsrapport 2020-Q3 |
2020-08-14 | X-dag halvårsutdelning NOVO B 3.25 |
2020-08-06 | Kvartalsrapport 2020-Q2 |
2020-05-06 | Kvartalsrapport 2020-Q1 |
2020-03-27 | X-dag halvårsutdelning NOVO B 5.35 |
2020-03-26 | Årsstämma |
2020-02-05 | Bokslutskommuniké 2019 |
2019-11-01 | Kvartalsrapport 2019-Q3 |
2019-08-21 | Kvartalsrapport 2019-Q2 |
2019-08-16 | X-dag halvårsutdelning NOVO B 3 |
2019-05-03 | Kvartalsrapport 2019-Q1 |
2019-03-22 | X-dag halvårsutdelning NOVO B 5.15 |
2019-03-21 | Årsstämma |
2019-02-01 | Bokslutskommuniké 2018 |
2018-08-18 | X-dag halvårsutdelning NOVO B 3 |
2018-08-08 | Kvartalsrapport 2018-Q2 |
2018-05-02 | Kvartalsrapport 2018-Q1 |
2018-03-23 | X-dag halvårsutdelning NOVO B 4.85 |
2018-03-22 | Årsstämma |
2018-02-01 | Bokslutskommuniké 2017 |
2017-11-01 | Kvartalsrapport 2017-Q3 |
2017-08-18 | X-dag halvårsutdelning NOVO B 3 |
2017-08-09 | Kvartalsrapport 2017-Q2 |
2017-05-03 | Kvartalsrapport 2017-Q1 |
2017-03-24 | X-dag ordinarie utdelning NOVO B 4.60 DKK |
2017-03-23 | Årsstämma |
2017-02-02 | Bokslutskommuniké 2016 |
2016-10-28 | Kvartalsrapport 2016-Q3 |
2016-08-12 | X-dag halvårsutdelning NOVO B 3 |
2016-08-05 | Kvartalsrapport 2016-Q2 |
2016-04-29 | Kvartalsrapport 2016-Q1 |
2016-03-21 | X-dag halvårsutdelning NOVO B 6.4 |
2016-03-18 | Årsstämma |
2016-02-03 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-08-06 | Kvartalsrapport 2015-Q2 |
2015-04-30 | Kvartalsrapport 2015-Q1 |
2015-03-20 | X-dag ordinarie utdelning NOVO B 5.00 DKK |
2015-03-19 | Årsstämma |
2015-01-30 | Bokslutskommuniké 2014 |
2014-10-30 | Kvartalsrapport 2014-Q3 |
2014-08-07 | Kvartalsrapport 2014-Q2 |
2014-05-01 | Kvartalsrapport 2014-Q1 |
2014-03-21 | X-dag ordinarie utdelning NOVO B 4.50 DKK |
2014-03-20 | Årsstämma |
2014-02-03 | Bokslutskommuniké 2013 |
2014-01-02 | Split NOVO B 1:5 |
2013-10-31 | Kvartalsrapport 2013-Q3 |
2013-08-08 | Kvartalsrapport 2013-Q2 |
2013-05-01 | Kvartalsrapport 2013-Q1 |
2013-03-21 | X-dag ordinarie utdelning NOVO B 18.00 DKK |
2013-03-20 | Årsstämma |
2013-02-04 | Bokslutskommuniké 2012 |
2012-10-31 | Kvartalsrapport 2012-Q3 |
2012-08-09 | Kvartalsrapport 2012-Q2 |
2012-04-27 | Kvartalsrapport 2012-Q1 |
2012-03-22 | X-dag ordinarie utdelning NOVO B 14.00 DKK |
2012-03-21 | Årsstämma |
2012-02-02 | Bokslutskommuniké 2011 |
2011-10-27 | Kvartalsrapport 2011-Q3 |
2011-08-04 | Kvartalsrapport 2011-Q2 |
2011-04-28 | Kvartalsrapport 2011-Q1 |
2011-03-24 | X-dag ordinarie utdelning NOVO B 10.00 DKK |
2011-03-23 | Årsstämma |
2011-02-02 | Bokslutskommuniké 2010 |
2010-03-25 | X-dag ordinarie utdelning NOVO B 7.50 DKK |
2007-12-03 | Split NOVO B 1:2 |
2001-04-04 | Split NOVO B 1:5 |
1997-01-02 | Split NOVO B 1:2 |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 17 August 2020 – On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme, initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.
Since the announcement of the programme, the following transactions have been made:
Number of B shares | Average purchase price | Transaction value, DKK | |
6 August 2020 | 115,000 | 402.54 | 46,292,373 |
7 August 2020 | 115,000 | 406.59 | 46,758,374 |
10 August 2020 | 115,000 | 406.94 | 46,798,239 |
11 August 2020 | 115,000 | 415.81 | 47,818,109 |
12 August 2020 | 112,000 | 418.72 | 46,897,030 |
13 August 2020 | 112,000 | 421.18 | 47,172,388 |
14 August 2020 | 110,000 | 416.75 | 45,842,291 |
Accumulated under the programme | 794,000 | 327,578,802 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 14,577 B shares in the period from 6 August 2020 to 14 August 2020. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 20,843,403 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 14 August 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 20,853,179 B shares at an average share price of DKK 425.76 per B share equal to a transaction value of DKK 8,878,366,533.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 50 / 2020